 WATERTOWN, Mass., Nov. 04, 2020 GLOBE NEWSWIRE -- Kymera Therapeutics, Inc. NASDAQ: KYMR, a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader therapeutics, today announced the company will present new preclinical data for its IRAKIMiD and STAT3 degrader programs at the 62nd American Society of Hematology ASH Annual Meeting taking place virtually from Dec. 5-8, 2020. 